FGF19 can also ameliorate sarcopenia and skeletal muscle atrophy induced by glucocorticoid treatment or obesity, suggesting that FGF19 and its analogs has potential therapeutic application for these symptoms. This evidence concerns the gene FGF19 and obesity due to melanocortin 4 receptor deficiency.